Notícias

Michael Barclay, lead manager of the Columbia Dividend Income fund, favors dividend growers over high yields.

Deal volume in 2026 is far outpacing last year, and is being driven by cancer and autoimmune disease drugs.

They have combined for 118 years of consecutive dividend increases.

J & J Snack Foods (NASDAQ:JJSF) reported fiscal second-quarter 2026 results that showed margin expansion and higher adjusted earnings despite a decline in sales, as management pointed to benefits from its “Project Apollo” transformation and ongoing portfolio reshaping. Chief Executive Officer D

It's hard to argue against its reliability.

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck. They settle in cash, clear immediately, and can be redeployed or spent without selling property or waiting on private placements. Pharma is one of the few sectors where mature franchises, regulatory ... 6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash

After another dizzying rally yesterday, Intel shares closed at $108.15 a share. With the latest 13% gain, the back-in-favor-again chip giant can claim these accolades: Its market cap of $544 billion, a record for the company, now exceeds that of Oracle and Johnson & Johnson, according to Dow Jones Market Data.

May 4 (Reuters) - Global drugmakers have been ramping up U.S. manufacturing and stockpiling inventory as the Trump administration moves to impose 100% tariffs on branded drugs unless companies cut